Tenofovir exalidex
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2010 (NCT01080820)
Timeline
Indications
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCCOCCCOP(=O)(O)CO[C@H](C)Cn1cnc2c(N)ncnc21- Mol. weight
- 569.73 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL515564 ↗
Also known as
- cmx157
- cmx157
- cmx157
- cmx 157
- cmx-157
- hdp-tenofovir
- hexadecyloxypropyl 9-(2-(phosphonomethoxy)propyl)adenine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02710604 | Phase 2 | May 1, 2016 | Hepion Pharmaceuticals |
| NCT02585440 | Phase 1 | Apr 1, 2016 | Hepion Pharmaceuticals |
| NCT01080820 | Phase 1 | Jun 1, 2010 | Chimerix, Covance |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hepion Pharmaceuticals | For profit | 2 | 2 | 2 | 2016 |
| Chimerix | For profit | 1 | 1 | 1 | 2010 |
| Covance | For profit | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1